Avenue Therapeutics, Inc. (ATXI) Research

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.

Market snapshot

Symbol
ATXI
Price
$0.33
Day change
+20.57%
Market cap
$1.1M
P/E ratio
-0.61x
52-week range
0.15-0.9699
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • Artelo Biosciences, Inc. (ARTL)
  • Carisma Therapeutics, Inc. (CARM)
  • Dermata Therapeutics, Inc. (DRMA)
  • PMGC Holdings Inc. (ELAB)
  • GT Biopharma, Inc. (GTBP)
  • NewcelX Ltd. (NCEL)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Psyence Biomedical Ltd. (PBM)

Recent insider activity

  • Fortress Biotech, Inc. — A-Award (111209 shares) on 2026-01-02
  • Fortress Biotech, Inc. — A-Award (33724 shares) on 2025-03-31
  • Fortress Biotech, Inc. — trade (0 shares) on 2024-12-31
  • Herskowitz Neil — S-Sale (23 shares) on 2024-12-02
  • KRANZLER JAY D — S-Sale (61 shares) on 2024-11-05

Open Avenue Therapeutics, Inc. (ATXI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.